Niagen CEO Says A Joint Venture For Its Rare-Disease Drug Is 'Very Possible' In 2027

Rob Fried says "we have a tiger by the tail" in NB4168, as third-quarter net sales came in at $27.2 million.

Share
Niagen CEO Says A Joint Venture For Its Rare-Disease Drug Is 'Very Possible' In 2027

Niagen Bioscience CEO Rob Fried said on the company's third-quarter earnings call Wednesday that a joint venture or separate financing for its NB4168 rare-disease drug program is "very possible" in 2027, while net sales for the quarter came in at $27.2 million.

A tiger by the tail

Niagen Bioscience makes Tru Niagen supplements and supplies its nicotinamide riboside, a form of vitamin B3, to ingredient customers. Asked by an H.C. Wainwright analyst about independent financing for NB4168, Fried said a joint venture or separate financing for the NAD Pharmaceuticals unit is

Vouchers and a $2 billion precedent

Chief Financial Officer Ozan Pamir pointed to two recent sales of rare pediatric disease priority review vouchers, valued at $203 million and $210 million each. He also said Shinogi agreed to pay $2 billion upfront for Intrabio after the FDA approved its therapy for ataxia telangiectasia.

Pamir said the IND-enabling studies, which precede human testing, should finish in early 2027, followed by a first-in-human study the company can "very easily afford." Fried said first-in-human work is planned for 2027, subject to completing development work and regulatory clearance.

The supplement business funding it

Tru Niagen sales were $23.3 million, down 10%, or $2.7 million, from a year earlier. Sales through its own website grew 13%. Ingredient revenue was $3.8 million, and Fried said one large ingredient customer faces competition from NMN products, with pricing still a hurdle.

The company reported a net loss of $1.2 million, or one cent a share, against net income of six cents a share a year earlier. It generated about $2.6 million in operating cash flow and ended the quarter with $69.5 million in cash and no debt. Management called 2026 an investment year, with marketing, research and general spending all expected to rise; Pamir said fourth-quarter revenue should improve from the third quarter. Pamir also said $14.6 million remains under its $20 million share buyback authorization.

Fried said that whether or not a financial deal happens, "if it's a great one, we'll do it."

Sources

More on Niagen Bioscience

All Niagen Bioscience (NAGE) coverage →